|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C17H22N4O3S2 |
|||
| Molecular Weight | 394.51 | CAS No. | 790702-57-7 | |
| Solubility (25°C)* | In vitro | DMSO | 79 mg/mL (200.24 mM) | |
| Water | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | NGI-1 is an aminobenzamide-sulfonamide compound that targets both oligosaccharyltransferase (OST) isoforms and therefore may exhibit antiviral activity against flaviviruses. | |
|---|---|---|
| Targets |
|
|
| In vitro | NGI-1 is a reversible catalytic subunit inhibitor of the oligosaccharyltransferase (OST) that has higher specificity for STT3B compared to STT3A (STT: OST catalytic subunit). In non-small cell lung cancer cells NGI-1 blocks cell surface localization and signaling of the EGFR glycoprotein, but selectively arrests proliferation in only those cell lines that are dependent on EGFR (or FGFR) for survival. In these cell lines OST inhibition causes cell cycle arrest accompanied by induction of p21, autofluorescence, and changes in cell morphology; all hallmarks of senescence[1]. NGI-1 exhibits broad antiviral activity against multiple flaviviruses. It blocks viral RNA replication independent of inhibition of the catalytic activity of the OST complex[2]. |
Protocol (from reference)
| Cell Assay: |
|
|---|
References
|
Selleck's NGI-1 has been cited by 3 publications
| ER Stress-Activated HSF1 Governs Cancer Cell Resistance to USP7 Inhibitor-Based Chemotherapy through the PERK Pathway [ Int J Mol Sci, 2024, 25(5)2768] | PubMed: 38474017 |
| Glycosylation of FGFR4 in cholangiocarcinoma regulates receptor processing and cancer signaling [ J Cell Biochem, 2022, 10.1002/jcb.30204] | PubMed: 34981854 |
| Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors [ Cancer Res, 2018, 78(17):5094-5106] | PubMed: 30026325 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.